LC
BMRN icon

Lindbrook Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lindbrook Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$67.7K Buy
958
+419
+78% +$28.2K 0.01% 852
2024
Q4 		$35.4K Buy
539
+150
+39% +$10K ﹤0.01% 964
2024
Q3 		$27.3K Buy
389
+111
+40% +$9.28K ﹤0.01% 1121
2024
Q2 		$22.9K Sell
278
-36
-11% -$3K ﹤0.01% 1166
2024
Q1 		$27.4K Sell
314
-71
-18% -$6.36K ﹤0.01% 1054
2023
Q4 		$37.1K Buy
385
+278
+260% +$24.6K ﹤0.01% 877
2023
Q3 		$9.47K Sell
107
-11
-9% -$979 ﹤0.01% 1442
2023
Q2 		$10.2K Buy
118
+1
+0.9% +$94 ﹤0.01% 1453
2023
Q1 		$11.4K Buy
117
+23
+24% +$2.38K ﹤0.01% 1367
2022
Q4 		$9.73K Sell
94
-95
-50% -$8.92K ﹤0.01% 1444
2022
Q3 		$16K Buy
189
+98
+108% +$8.73K ﹤0.01% 1094
2022
Q2 		$8K Buy
91
+19
+26% +$1.51K ﹤0.01% 1338
2022
Q1 		$6K Sell
72
-10
-12% -$837 ﹤0.01% 1500
2021
Q4 		$7K Buy
82
+45
+122% +$3.71K ﹤0.01% 1391
2021
Q3 		$3K Buy
37
+3
+9% +$237 ﹤0.01% 1381
2021
Q2 		$3K Buy
34
+5
+17% +$396 ﹤0.01% 1442
2021
Q1 		$2K Sell
29
-66
-69% -$5.39K ﹤0.01% 1521
2020
Q4 		$8K Buy
95
+51
+116% +$4.04K ﹤0.01% 981
2020
Q3 		$3K Buy
44
+2
+5% +$202 ﹤0.01% 1242
2020
Q2 		$5K Buy
42
+6
+17% +$596 ﹤0.01% 1069
2020
Q1 		$3K Buy
36
+10
+38% +$862 ﹤0.01% 1158
2019
Q4 		$2K Sell
26
-69
-73% -$5.21K ﹤0.01% 1263
2019
Q3 		$6K Sell
95
-293
-76% -$22.6K ﹤0.01% 1017
2019
Q2 		$33K Buy
388
+26
+7% +$2.22K 0.01% 538
2019
Q1 		$32K Hold
362
– – 0.01% 540
2018
Q4 		$30K Buy
+362
New +$34.4K 0.01% 497

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's BMRN Position: Q1 2025 in Review

Lindbrook Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 78% in Q1 2025, buying an estimated $28.2K and bringing the position to 958 shares worth $67.7K. The position accounts for 0.01% of the portfolio, ranked #852.

Lindbrook Capital first reported a position in BMRN in Q4 2018 and has held it in 26 quarters since. 585 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Lindbrook Capital held 958 shares of BioMarin Pharmaceuticals worth $67.7K as of Q1 2025.
  • Lindbrook Capital bought 419 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $28.2K.
  • BioMarin Pharmaceuticals made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #852 holding.
  • Lindbrook Capital first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • 585 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.